TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05660980: Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 90 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,224,510

Rescue Site Savings

+$799,680

Unlock Full NCT05660980 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05660980 Rescue Dossier →